Orchard’s Gene Therapy Under Fast-Track Review At EMA
Executive SummaryA handful of new products are under review at the European Medicines Agency. Orchard Therapeutics' gene therapy application will be fast-tracked; Roche's filing for its new flu treatment will not.
You may also be interested in...
On the cusp of US approval, Amarin must wait until late 2020 for EMA judgement